Standing genetic variation and the evolution of drug resistance in HIV

PLoS Computational Biology

Volumn 8, Issue 6, 2012, Pages

  Pennings, Pleuni Simone ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG DOSAGE; GENES; POPULATION STATISTICS; VIRUSES;

'CURRENT; COMBINATION THERAPY; DRUG COMBINATIONS; DRUG-RESISTANCE; GENETIC VARIATION; GOOD DATA; POPULATION GENETIC MODELS; SINGLE-DOSE; THERAPY TREATMENT; TWO SOURCES;

PROBABILITY;

NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TREATMENT FAILURE; GENETIC DRIFT; GENETIC MODEL; GENETIC SELECTION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR EVOLUTION; MUTATION RATE; POLYPHARMACY; POPULATION DYNAMICS; POPULATION SIZE; PREDICTION; PROBABILITY; VIRUS LOAD; VIRUS MUTATION; VIRUS PARTICLE; VIRUS RESISTANCE; VIRUS TRANSMISSION; BIOLOGICAL MODEL; BIOLOGY; DISEASE TRANSMISSION; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MUTATION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; TREATMENT FAILURE; VERTICAL TRANSMISSION; VIROLOGY; VIRUS GENE;

ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENES, VIRAL; GENETIC VARIATION; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MODELS, GENETIC; MUTATION; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84864068244     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002527     Document Type: Article

References (60)

1. Barrett RDH, Schluter D, (2008) Adaptation from standing genetic variation. Trends Ecol Evol 23: 38-44.
2. Harrigan PR, Whaley M, Montaner JS, (1999) Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13: F59-F62.
3. Cozzi-Lepri A, Dunn D, Pillay D, Sabin CA, Fearnhill E, et al. (2010) Long-term probability of detecting drug-resistant hiv in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 50: 1275-1285.
4. Johnson V, Brun-Vezinet F, Clotet B, Guenthard H, Kuritzkes D, et al. (2010) Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18: 156-63.
5. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across europe in patients infected with hiv-1. Lancet 352: 1725-1730.
6. Deeks SG, Smith M, Holodniy M, Kahn JO, (1997) Hiv-1 protease inhibitors- a review for clinicians. JAMA 277: 145-153.
7. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, et al. (2010) Pre-existing minority drug-resistant hiv-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201: 662-671.
8. Gianella S, Richman DD, (2010) Minority variants of drug-resistant hiv. J Infect Dis 202: 657-666.
9. Johnson JA, Geretti AM, (2010) Low-frequency hiv-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 65: 1322-1326.
10. Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, et al. (2009) Low-frequency k103n strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 52: 569-573.
11. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency hiv-1 drug resistance mutations and risk of nnrti-based antiretroviral treatment failure a systematic review and pooled analysis. JAMA 305: 1327-1335.
12. Bonhoeffer S, Nowak MA, (1997) Pre-existence and emergence of drug resistance in hiv-1 infection. Proc Biol Sci 264: 631-637.
13. Ribeiro RM, Bonhoeffer S, Nowak MA, (1998) The frequency of resistant mutant virus before antiviral therapy. AIDS 12: 461-465.
14. Hermisson J, Pennings PS, (2005) Soft sweeps: Molecular population genetics of adaptation from standing genetic variation. Genetics 169: 2335-2352.
15. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, et al. (2007) Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of hiv-1: a meta-analysis. Int J Epidemiol 36: 1009-1021.
16. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, et al. (2010) Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 363: 1499-1509.
17. Tam LWY, Chui CKS, Brumme CJ, Bangsberg DR, Montaner JSG, et al. (2008) The relationship between resistance and adherence in drug-naive individuals initiating haart is specific to individual drug classes. J Acquir Immune Defic Syndr 49: 266-271.
18. Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, et al. (2010) Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 24: 395-403.
19. Lima VD, Harrigan PR, Senecal M, Yip B, Druyts E, et al. (2010) Epidemiology of antiretroviral multiclass resistance. Am J Epidemiol 172: 460-468.
20. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L, et al. (2003) Drug resistance mutations during structured treatment interruptions. Antivir Ther 8: 411-415.
21. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, et al. (2006) Cd4-guided structured antiretroviral treatment interruption strategy in hiv-infected adults in west africa (trivacan anrs 1269 trial): a randomised trial. Lancet 367: 1981-1989.
22. Danel C, Moh R, Chaix ML, Gabillard D, Gnokoro J, et al. (2009) Two-months-off, four-months-on an-tiretroviral regimen increases the risk of resistance, compared with continuous therapy: A randomized trial involving west african adults. J Infect Dis 199: 66-76.
23. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) Cd4+count-guided inter-ruption of antiretroviral treatment. New Engl J Med 355: 2283-2296.
24. Taylor S, Boffito M, Khoo S, Smit E, Back D, (2007) Stopping antiretroviral therapy. AIDS 21: 1673-1682.
25. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22: 2279-2289.
26. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, et al. (2003) Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 188: 388-396.
27. Arnedo-Valero M, Garcia F, Gil C, Guila T, Fumero E, et al. (2005) Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic hiv infection. Clin Infect Dis 41: 883-890.
28. Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, et al. (2006) A pilot study evaluating time to cd4 t-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: Results of actg a5102. J Acquir Immune Defic Syndr 42: 140-148.
29. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, et al. (2007) Antiretroviral therapy interruption guided by cd4 cell counts and plasma hiv-1 rna levels in chronically hiv-1-infected patients. AIDS 21: 169-178.
30. Darwich L, Esteve A, Ruiz L, Paredes R, Bellido R, et al. (2008) Drug-resistance mutations number and k70r or t215y/f substitutions predict treatment resumption during guided treatment interruptions. AIDS Res Hum Retroviruses 24: 725-732.
31. Davey RT, Bhat N, Yoder C, Chun TW, Metcalf JA, et al. (1999) Hiv-1 and t cell dynamics after interruption of highly active antiretroviral therapy (haart) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96: 15109-15114.
32. Haldane JBS, (1927) A mathematical theory of natural and artificial selection, part v: Selection and mutation. Proc Camb Philol Soc 23: 838-844.
33. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
34. Gadhamsetty S, Dixit NM, (2010) Estimating frequencies of minority nevirapine-resistant strains in chronically hiv-1-infected individuals naive to nevirapine by using stochastic simulations and a math-ematical model. J Virol 84: 10230-10240.
35. Harrigan PR, Hogg RS, Dong WWY, Yip B, Wynhoven B, et al. (2005) Predictors of hiv drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339-347.
36. Margot NA, Lu B, Cheng A, Miller MD, Study T, (2006) Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in study 903. HIV Med 7: 442-450.
37. Mansky LM, Temin HM, (1995) Lower in vivo mutation rate of human-immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
38. Martinez-Picado J, Martinez MA, (2008) Hiv-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 134: 104-123.
39. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, et al. (2009) In vivo fitness cost of the m184v mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. Journal of Virology 83: 2038-2043.
40. Wang DN, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, et al. (2011) Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol 85: 6403-6415.
41. Fu YX, (2001) Estimating mutation rate and generation time from longitudinal samples of dna sequences. Mol Biol Evol 18: 620-626.
42. Leigh-Brown AJ, (1997) Analysis of hiv-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci U S A 94: 1862-1865.
43. Rouzine IM, Coffin JM, (1999) Linkage disequilibrium test implies a large effective population number for hiv in vivo. Proc Natl Acad Sci U S A 96: 10758-10763.
44. BrunVezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, et al. (1997) Hiv-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the delta trial. Lancet 350: 983-990.
45. van Heeswijk RPG, Veldkamp AI, Mulder JW, Meenhorst PL, Wit F, et al. (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in hiv-1-infected individuals. AIDS 14: F77-F82.
46. van Heeswijk RPG, Veldkamp A, Mulder JW, Meenhorst PL, Lange JMA, et al. (2001) Combination of protease inhibitors for the treatment of hiv-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6: 201-229.
47. Pirillo M, Palmisano L, Pellegrini M, Galluzzo C, Weimer L, et al. (2010) Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: A substudy of the iss-part trial. AIDS Res Hum Retroviruses 26: 541-545.
48. Garcia F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, et al. (2001) The virological and immunological consequences of structured treatment interruptions in chronic hiv-1 infection. AIDS 15: F29-F40.
49. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, et al. (2005) Delay of hiv-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11: 615-622.
50. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, et al. (2003) Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17: F33-F37.
51. Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, et al. (2005) Structured treatment inter-ruptions in primary hiv-1 infection- the anrs 100 primstop trial. J Acquir Immune Defic Syndr 40: 307-316.
52. Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, et al. (2007) Determinants of virologic and immunologic outcomes in chronically hiv-infected subjects undergoing repeated treatment interruptions- the istituto superiore di sanita-pulsed antiretroviral therapy (iss-part) study. J Acquir Immune Defic Syndr 46: 39-47.
53. Reynolds SJ, Kityo C, Mbamanya F, Dewar R, Ssali F, et al. (2009) Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in uganda. Antivir Ther 14: 293-297.
54. Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, et al. (2010) A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of hiv infection in Uganda. Plos One 5: e10307.
55. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman J, et al. (2004) Efficacy and safety of tenofovir df vs stavuldine in combination therapy in antiretroviral-naive patients- a 3-year randomized trial. JAMA 292: 191-201.
56. Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, et al. (2007) Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal hiv prevention: an open-label randomised trial. Lancet 370: 1698-1705.
57. Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, et al. (2010) Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent hiv-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis 50: 898-908.
58. Kepler TB, Perelson AS, (1998) Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci U S A 95: 11514-11519.
59. Tomasetti C, (2011) A new hypothesis: imatinib affects leukemic stem cells in the same way it affectsall other leukemic cells. Blood Cancer J 1: e19.
60. Weis SE, Slocum PC, Blais FX, King B, Nunn M, et al. (1994) The effect of directly observed therapy on the rates of drug-resistance and relapse in tuberculosis. N Engl J Med 330: 1179-1184.